Japan's Taisho has granted all commercial rights to its preclinical schizophrenia drug outside of Japan to Pfizer for $22 million up front. TS-032 is an mGluR agonist, which promises to influence the transmission of substances in the brain that is associated with schizophrenia. Taisho is an experienced player in the psychiatric drugs market. The Japanese company also stands to gain unspecified milestone payments for the drug.
- see this release [1]
- read the AP report [2]
Related Articles:
Lilly bows out of diabetes deal with Taisho. Report [3]
New therapy found for schizophrenia. Report [4]
Links:
[1] http://www.fiercebiotech.com/press-releases/hikal-announces-manufacturing-agreement-pfizer-supply-api-s
[2] http://www.businessweek.com/ap/financialnews/D8U125080.htm
[3] http://www.fiercebiotech.com/story/lilly-bows-out-of-diabetes-deal-with-taisho/2006-08-07
[4] http://www.fiercebioresearcher.com/story/new-therapy-found-schizophrenia/2007-09-25